Cargando…

Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma

BACKGROUND: The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wen-Xiao, Huang, Jia-Jia, Li, Wen-Yu, Zhang, Xu, Xia, Yi, Jiang, Wen-Qi, Fan, Wei, Li, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668634/
https://www.ncbi.nlm.nih.gov/pubmed/26630874
http://dx.doi.org/10.1186/s40880-015-0057-z
_version_ 1782404000356761600
author Wei, Wen-Xiao
Huang, Jia-Jia
Li, Wen-Yu
Zhang, Xu
Xia, Yi
Jiang, Wen-Qi
Fan, Wei
Li, Zhi-Ming
author_facet Wei, Wen-Xiao
Huang, Jia-Jia
Li, Wen-Yu
Zhang, Xu
Xia, Yi
Jiang, Wen-Qi
Fan, Wei
Li, Zhi-Ming
author_sort Wei, Wen-Xiao
collection PubMed
description BACKGROUND: The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been clearly defined. The aim of the present study was to assess the prognostic value of PET/CT scanning during different treatment processes of Burkitt’s lymphoma. METHODS: A total of 29 adult patients with newly diagnosed Burkitt’s lymphoma were retrospectively involved in this study; of them, 23 patients underwent baseline PET/CT, 15 patients underwent mid-therapy PET/CT after 1–4 cycles of chemotherapy, and 17 patients underwent post-therapy PET/CT after all planned first-line chemotherapy cycles. Mid-therapy and post-therapy PET/CT results (positive vs. negative) were visually interpreted according to the criteria of the International Harmonization Project. The reduction in the maximum standardizes uptake values (∆SUVmax) of 25%, 50%, and 75% were regarded as cutoff points. Overall survival (OS) and progression-free survival (PFS) were regarded as the major endpoints. RESULTS: The median OS and PFS were 27.6 months (range 6.5–78.3 months) and 27.2 months (range 3.0–78.3 months), respectively. The median SUVmax of the baseline PET/CT was 18.3 (range 1.6–35.9), whereas the median SUVmax of the mid-therapy and post-therapy PET/CT decreased to 4.0 (range 0–17.6) and 3.0 (range 0–14.5), respectively. The patients’ Eastern Cooperative Oncology Group (ECOG) scores (<2 vs. ≥2) were significantly associated with the baseline PET/CT SUVmax. The mid-therapy and post-therapy PET/CT results (positive vs. negative) showed no significant association with OS or PFS. The optimal cutoff ∆SUVmax from the baseline to the post-therapy PET/CT that could predict a change in OS in patients with Burkitt’s lymphoma was 50% (P = 0.019). CONCLUSIONS: (18)F-FDG uptake was intense in Burkitt’s lymphoma, and there was a significant reduction in SUVmax during the interim and post-therapy PET/CT procedures. A ∆SUVmax of greater than 50% was a favorable cutoff point to predict the OS of Burkitt’s lymphoma patients.
format Online
Article
Text
id pubmed-4668634
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46686342015-12-09 Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma Wei, Wen-Xiao Huang, Jia-Jia Li, Wen-Yu Zhang, Xu Xia, Yi Jiang, Wen-Qi Fan, Wei Li, Zhi-Ming Chin J Cancer Original Article BACKGROUND: The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been clearly defined. The aim of the present study was to assess the prognostic value of PET/CT scanning during different treatment processes of Burkitt’s lymphoma. METHODS: A total of 29 adult patients with newly diagnosed Burkitt’s lymphoma were retrospectively involved in this study; of them, 23 patients underwent baseline PET/CT, 15 patients underwent mid-therapy PET/CT after 1–4 cycles of chemotherapy, and 17 patients underwent post-therapy PET/CT after all planned first-line chemotherapy cycles. Mid-therapy and post-therapy PET/CT results (positive vs. negative) were visually interpreted according to the criteria of the International Harmonization Project. The reduction in the maximum standardizes uptake values (∆SUVmax) of 25%, 50%, and 75% were regarded as cutoff points. Overall survival (OS) and progression-free survival (PFS) were regarded as the major endpoints. RESULTS: The median OS and PFS were 27.6 months (range 6.5–78.3 months) and 27.2 months (range 3.0–78.3 months), respectively. The median SUVmax of the baseline PET/CT was 18.3 (range 1.6–35.9), whereas the median SUVmax of the mid-therapy and post-therapy PET/CT decreased to 4.0 (range 0–17.6) and 3.0 (range 0–14.5), respectively. The patients’ Eastern Cooperative Oncology Group (ECOG) scores (<2 vs. ≥2) were significantly associated with the baseline PET/CT SUVmax. The mid-therapy and post-therapy PET/CT results (positive vs. negative) showed no significant association with OS or PFS. The optimal cutoff ∆SUVmax from the baseline to the post-therapy PET/CT that could predict a change in OS in patients with Burkitt’s lymphoma was 50% (P = 0.019). CONCLUSIONS: (18)F-FDG uptake was intense in Burkitt’s lymphoma, and there was a significant reduction in SUVmax during the interim and post-therapy PET/CT procedures. A ∆SUVmax of greater than 50% was a favorable cutoff point to predict the OS of Burkitt’s lymphoma patients. BioMed Central 2015-12-02 /pmc/articles/PMC4668634/ /pubmed/26630874 http://dx.doi.org/10.1186/s40880-015-0057-z Text en © Wei et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Wei, Wen-Xiao
Huang, Jia-Jia
Li, Wen-Yu
Zhang, Xu
Xia, Yi
Jiang, Wen-Qi
Fan, Wei
Li, Zhi-Ming
Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
title Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
title_full Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
title_fullStr Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
title_full_unstemmed Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
title_short Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
title_sort prognostic values of interim and post-therapy (18)f-fdg pet/ct scanning in adult patients with burkitt’s lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668634/
https://www.ncbi.nlm.nih.gov/pubmed/26630874
http://dx.doi.org/10.1186/s40880-015-0057-z
work_keys_str_mv AT weiwenxiao prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT huangjiajia prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT liwenyu prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT zhangxu prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT xiayi prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT jiangwenqi prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT fanwei prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma
AT lizhiming prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma